Relevance of Sarcopenia in Advanced Liver Disease
Patients with established liver cirrhosis, or end-stage liver disease (ESLD), are at high risk of developing liver cancer (hepatic carcinoma; HCC), portal hypertension, and sarcopenia, all which lead to significant morbidity and mortality. In this patient group the annual incidence of HCC is c. 2-8% and these patients
| Condition(s) | Liver Cirrhosis, Hepatocellular Carcinoma, Sarcopenia, Portal Hypertension |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Patients with established liver cirrhosis, or end-stage liver disease (ESLD), are at high risk of developing liver cancer (hepatic carcinoma; HCC), portal hypertension, and sarcopenia, all which lead to significant morbidity and mortality. In this patient group the annual incidence of HCC is c. 2-8% and these patients are therefore included in ultrasound HCC screening programs every 6 months. In this study, the investigators are aiming to assess sarcopenia, clinically significant portal hypertension (CSPH), and HCC with a single short magnetic resonance (MR) examination. A neck-to-knee MRI-examination will be acquired to derive body composition profile (BCP) measurements including visceral and abdominal subcutaneous adipose tissue (VAT and ASAT), thigh fat free muscle volume (FFMV) and mus |
| Who can participate | Inclusion Criteria: 1. Established or probable liver cirrhosis according to clinical practice at the Department of Gastroenterology and Hepatology at Linköping University Hospital. This is not by necessity biopsy verified, it can be different criteria such as FibroScan, symptoms, biopsy, and radiology. 2. Age ≥18 years 3. Written informed consent from the participant Exclusion Criteria: 1. Contraindications for MRI 2. Subjects suffering from primary sclerosing cholangitis (PSC) 3. Subjects diagnosed with Hepatic carcinoma (HCC) 4. Previous liver transplant |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Linkoeping University |
| Locations | Eksjö, Sweden; Jönköping, Sweden; Linköping, Sweden |
| Start date | 2021-02-01 |
| NCT ID | NCT05502198 |
| Official listing | https://clinicaltrials.gov/study/NCT05502198 |